| Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | where is DA input lost in PD |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | after 60-80 of nigral DA cell bodies are out |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tremor, bradykinesia, rigidity, postural defect |  | 
        |  | 
        
        | Term 
 
        | mech of inheritance of Huntington's |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | where is most of the cell degredation in HD? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | chorea, progressive dementia |  | 
        |  | 
        
        | Term 
 
        | what is the meso/neostriatal system |  | Definition 
 
        | DA projection from nigra to neostriatum |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is the role of the neostrial system |  | Definition 
 
        | initiation and maint of movement |  | 
        |  | 
        
        | Term 
 
        | what is the mesolimbocortical system? |  | Definition 
 
        | DA from midbrain to limbic/cortical structures |  | 
        |  | 
        
        | Term 
 
        | what is the role of the mesolimbocortical system? |  | Definition 
 
        | regulation of cognitive/emotional processes |  | 
        |  | 
        
        | Term 
 
        | what is the hypothalamo-hypophyseal system? |  | Definition 
 
        | hypothal DA neurons releasing DA into portal system |  | 
        |  | 
        
        | Term 
 
        | what is the chemoreceptor trigger zone? |  | Definition 
 
        | DA in area postrema induces N+V |  | 
        |  | 
        
        | Term 
 
        | what two parts of the dopamine system are affected in PD? |  | Definition 
 
        | neostriatal, mesolimbocortical (sometimes) |  | 
        |  | 
        
        | Term 
 
        | what is the source of most symptomes of PD? |  | Definition 
 
        | disinhibition of the indirect movement inhibitory pathway: striatal-pallidal-subthal-pallidal-thal-cortical loop |  | 
        |  | 
        
        | Term 
 
        | course of PD treatment (general classes) |  | Definition 
 
        | MAOi, DA releaser, DA ag, DA precursor, COMTi |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | dyskinesia, confusion/delirium, hallucinations, paranoia, anx, n+v |  | 
        |  | 
        
        | Term 
 
        | other clinical uses of l-dopa |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | why should l-dopa not be taken w/ food? |  | Definition 
 
        | competes w/ aa transporters, inhibited by low gastric pH |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | other clinical uses of bromocriptine? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | problem with oral admin of bromocriptine? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | bromocriptine and albumin? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | anorexia, n+v, hypoTN, arryth, dyskinesis, psych |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | restlessness, insom, irritable, conf; enhanced effects of anti-cholinergics |  | 
        |  | 
        
        | Term 
 
        | active metabolite of selegiline |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | striatal NT in indirect pathway |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | striatal NT in direct pathway |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | striatal NT in interneurons |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | DR in interneuron pathway |  | Definition 
 | 
        |  |